Lipase variants and polynucleotides encoding same

US11268076B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11268076-B2
Application numberUS-201515526834-A
CountryUS
Kind codeB2
Filing dateDec 8, 2015
Priority dateDec 9, 2014
Publication dateMar 8, 2022
Grant dateMar 8, 2022

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to a variant of a parent lipase, which parent lipase has the amino acid sequence of SEQ ID NO: 2, wherein the variant has lipase activity, comprises a substitution at a position corresponding to position 51 and comprises a substitution or remains unaltered at a position corresponding to position 96 of SEQ ID NO: 2. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

First claim

Opening claim text (preview).

The invention claimed is: 1. A lipase variant which (a) comprises a V at a position corresponding to position 51 of SEQ ID NO: 2 and comprises a substitution or is unaltered at a position corresponding to position 96 of SEQ ID NO: 2, (b) has at least 97% but less than 100% sequence identity to SEQ ID NO: 2, (c) has improved stability as compared to the polypeptide of SEQ ID NO: 2, and (d) has lipase activity. 2. The lipase variant of claim 1 , which is unaltered at a position corresponding to position 96 of SEQ ID NO: 2. 3. The lipase variant of claim 1 , which comprises a substitution at a position corresponding to position 96 of SEQ ID NO: 2. 4. The lipase variant of claim 3 , wherein the substitution at a position corresponding to position 96 of SEQ ID NO: 2 is with Asp, Leu, or Trp. 5. The lipase variant of claim 1 , further comprising one or more amino acid substitutions corresponding to the following substitutions of SEQ ID NO: 2, selected from the group consisting of: V2F/G/H/K/R/Y; N33H/K/R/P/Q; S54T; E56H/K/R; D57G/N; T64S; L69H/K/R; K98E/D/I/R/T/V; E87E/F/H/I/K/M/Q/R; N101D/E; K163G/P; V176L; E210H/K/R; Y220F; A243P/S/T; W260F/Y; and L269I/V. 6. The lipase variant of claim 2 , further comprising one or more amino acid substitutions corresponding to the following substitutions of SEQ ID NO: 2, selected from the group consisting of: V2F/G/H/K/R/Y; N33H/K/R/P/Q; S54T; E56H/K/R; D57G/N; T64S; L69H/K/R; K98E/D/I/R/T/V; E87E/F/H/I/K/M/Q/R; N101D/E; K163G/P; V176L; E210H/K/R; Y220F; A243P/S/T; W260F/Y; and L269I/V. 7. The lipase variant of claim 4 , further comprising one or more amino acid substitutions corresponding to the following substitutions of SEQ ID NO: 2, selected from the group consisting of: V2F/G/H/K/R/Y; N33H/K/R/P/Q; S54T; E56H/K/R; D57G/N; T64S; L69H/K/R; K98E/D/I/R/T/V; E87E/F/H/I/K/M/Q/R; N101D/E; K163G/P; V176L; E210H/K/R; Y220F; A243P/S/T; W260F/Y; and L269I/V. 8. The lipase variant of claim 1 , comprising a set of amino acid substitutions corresponding to the following substitutions of SEQ ID NO: 2, selected from the group consisting of: a. V2K+N33K+F51V+S54T+L69R+K98E+V176L+E210K+W260Y; b. V2K+N33K+F51V+L69R+K98E+V176L+V187P+E210K+L227G; c. V2K+N33K+F51V+L69R+K98E+V176L+E210K+S224F+L227G; d. V2K+N33K+F51V+L69R+K98E+V176L+E210K+L227G; e. V2K+N33K+F51V+L69R+K98E+V176L+E210K+L227G+V228P; f. V2K+N33K+F51V+L69R+K98E+E210K+L227G; g. V2K+N33K+F51V+V187P; h. V2K+N33K+F51V+S224F; i. V2K+N33K+F51V+L227D; j. V2K+N33K+F51V+V228P; k. V2K+F51V; I. V2Y+N33K+F51V; m. V2Y+N33K+F51V+E56K+L69R+E96D+K98E; and n. V2Y+N33K+F51V+E56K+L69R+K98E. 9. The lipase variant of claim 1 , comprising a set of amino acid substitutions corresponding to the following substitutions of SEQ ID NO: 2, selected from the group consisting of: a. N33K+F51V; b. N33K+F51V+S54T+E56K+L69R+K98E+W260Y; c. N33K+F51V+S54T+E56K+K98E+E210K+W260Y; d. N33K+F51V+S54T+E56K+K98I; e. N33K+F51V+S54T+E56K+K98I+T143A; f. N33K+F51V+S54T+L69R+E87K+K98E+E210K+Y220F; g. N33K+F51V+S54T+K98E+W260Y; h. N33K+F51V+S54T+K98I; i. N33K+F51V+E56K+L69R+E96D+K98E; j. N33K+F51V+E56K+L69R+E96D+K98E+V187D; k. N33K+F51V+E56K+L69R+E96D+K98E+G225P; l. N33K+F51V+E56K+L69R+K98E; m. N33K+F51V+E56K+L69R+K98E+V176L+E210K+Y220F; n. N33K+F51V+E56K+L69R+K98E+V176L+E210K+W260Y; o. N33K+F51V+E56K+L69R+K98E+V187D; p. N33K+F51V+E56K+L69R+K98E+E210K; q. N33K+F51V+E56K+L69R+K98E+G225P; r. N33K+F51V+E56K+L69R+K98E+T256P; s. N33K+F51V+E56K+K98E+K163P+E210K; t. N33K+F51V+E56K+K98E+V176L+E210K+Y220F; u. N33K+F51V+D57G+K98I; v. N33K+F51V+L69R+K98E; w. N33K+F51V+L69R+K98E+V176L+E210K+L227G; x. N33K+F51V+L93I+N94R+F95V y. N33K+F51V+K98E; z. N33K+F51V+K98E+E210R+W260Y; aa. N33K+F51V+K98I; bb. N33K+F51V+K98I +H198S+Y220F; cc. N33K+F51V+K98I+Y220F; dd. N33P+F51V; ee. N33P+F51V+D57G+E210K; and ff. N33P+F51V+K98E. 10. The lipase variant of claim 1 , comprising a set of amino acid substitutions corresponding to the following substitutions of SEQ ID NO: 2, selected from the group consisting of: a. F51V; b. F51V+E56K+L69R+K98E; c. F51V+E56K+E87K+K98E; d. F51V+D57G+N101D+E210K; e. F51V+L69R+E87K+K98E; f. F51V+L69R+K98E+E210K; g. F51V+I86P+E87A+G91A+N92D+F95Y+D96T+L97P+K98Q+T252I+T255I; h. F51V+E87K+K98E; i. F51V+K98E+N101D; j. F51V+K98E+E210K; and k. F51V+V176L. 11. The lipase variant of claim 1 , further comprising an alteration at any of positions: 4, 27, 33, 38, 57, 58, 60, 83, 86, 91, 94, 97, 99, 111, 150, 163, 210, 216, 225, 227, 231, 249, 254, 255, 256, 263, 264, 265, 266, 267, and 269 of SEQ ID NO: 2. 12. The lipase variant of claim 1 , wherein the improved stability is stability in detergent compositions, stability in detergent compositions containing protease, stability in the presence of protease, stability under storage conditions, stability under storage conditions in the presence of protease, or thermostability, as compared to the lipase of SEQ ID NO: 2. 13. A detergent composition comprising the lipase variant of claim 1 and a surfactant. 14. A detergent composition comprising the lipase variant of claim 2 and a surfactant. 15. A detergent composition comprising the lipase variant of claim 3 and a surfactant. 16. A detergent composition comprising the lipase variant of claim 4 and a surfactant.

Assignees

Inventors

Classifications

  • Carboxylic ester hydrolases (3.1.1) · CPC title

  • containing lipase · CPC title

  • C12N9/20Primary

    Triglyceride splitting, e.g. by means of lipase · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11268076B2 cover?
The present invention relates to a variant of a parent lipase, which parent lipase has the amino acid sequence of SEQ ID NO: 2, wherein the variant has lipase activity, comprises a substitution at a position corresponding to position 51 and comprises a substitution or remains unaltered at a position corresponding to position 96 of SEQ ID NO: 2. The present invention also relates to polynucleoti…
Who is the assignee on this patent?
Novozymes As
What technology area does this patent fall under?
Primary CPC classification C12N9/20. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).